Fertility M&A Update 2026

Fertility M&A in 2026: a maturing market, a more selective buyer, and what it means for independent clinics

When we last wrote about the fertility M&A market in February 2025, the sector had already attracted significant investor attention.

The logic was clear. Fertility is a large, growing and increasingly private-pay healthcare market. It benefits from powerful demographic and social tailwinds, including people starting families later, more single women and same sex couples accessing treatment, growing demand for egg freezing and fertility preservation, and continued pressure on NHS funded IVF.

That underlying logic still holds. What has changed is the texture of the market. We have not seen a flood of new UK fertility clinic deals; in fact, publicly announced UK clinic transactions have been relatively limited. What we have seen is further evidence that the market is maturing, that scale matters, and that investor interest is broadening beyond clinic ownership into the wider fertility ecosystem.

For independent clinic owners, that combination of strong fundamentals but a more discerning buyer, is the most important thing to understand about today’s market. It is genuinely good news for well run clinics, but it raises the bar on preparation.

The UK fertility market has continued to grow

The latest HFEA data shows the scale of the sector.

In 2024, around 64,000 patients underwent more than 100,000 treatment and freezing cycles at HFEA licensed clinics. Around 53,000 patients had IVF, and approximately 21,400 babies were born from IVF treatment.

That means around 1 in 31 UK births in 2024 came from IVF.

This is no longer a small, niche part of private healthcare. Fertility treatment is now a mainstream healthcare market, and one that continues to grow in importance as broader birth rates fall.

The ONS reported that the total fertility rate in England and Wales fell to 1.41 children per woman in 2024, the lowest level on record for the third consecutive year. At the same time, the average age of mothers continued to rise, with the standardised mean age reaching 31.0.

That combination matters. Fewer people are having children, many are having them later, and more people are needing clinical support when they do decide to start a family.

NHS funding remains the key commercial driver, with one caveat worth watching

The continued reduction in NHS-funded IVF remains one of the most important commercial drivers in the sector.

HFEA data shows that NHS-funded IVF cycles fell from 35% of UK IVF cycles in 2019 to 28% in 2024. In England the fall has been steeper, from around 32% in 2019 to 25% in 2024. There is also substantial regional variation: in 2024, NHS funded cycles ranged from roughly half of cycles in the North East to around a fifth in the South West and East Midlands.

This creates an obvious access issue for patients, but from an M&A perspective it reinforces the private-pay opportunity. Where NHS access is limited, inconsistent or slow, more patients either self-fund treatment or look for alternative routes into the pathway.

There is, however, one development that runs against this grain, and it would be a mistake to ignore it. In March 2026, NICE published its first comprehensive update to its fertility guidance since 2013. The updated guideline actually recommends more NHS provision, three full IVF cycles for eligible women under 40, with up to three further cycles considered where the initial cycles are unsuccessful. Taken at face value, fuller NHS funding would soften the private-pay thesis.

In practice, we do not expect this to reverse the trend in the near term. The 2013 guideline made a similar three cycle recommendation that was never fully implemented, because commissioning is controlled by individual ICBs rather than NICE, and NHS funding has fallen since, not risen, despite that guidance. The realistic read is that private-pay dynamics remain firmly intact for the foreseeable future, but the gap between national guidance and local commissioning is now a genuine “watch item” rather than a settled certainty. Buyers are alert to it, and sellers should expect questions about NHS exposure and how resilient their private-pay mix is.

None of this makes fertility an easy market. It is emotionally sensitive, highly regulated and clinically complex. It does, however, create a strong demand backdrop for well run operators with clear pricing, strong outcomes, good patient experience and effective digital patient acquisition.

Consolidation has continued, but selectively

The two most notable UK fertility clinic transactions since our last update were:

Amulet Capital Partners’ investment in TFP Fertility Group

In May 2026, Amulet Capital Partners announced its acquisition of TFP Fertility Group from Benefit Street Partners.

TFP operates an integrated network of 10 fertility clinics and 21 satellite and referral centres across the UK and Poland. The deal represents a further sponsor-backed ownership change in one of the more established fertility platforms in the UK and Northern Europe.

The significance is not just that TFP changed hands. It is that a dedicated healthcare investor saw enough long term opportunity in the market to back a scaled fertility platform.

FutureLife Group’s acquisition of Herts & Essex Fertility Centre

In March 2026, FutureLife Group announced the acquisition of Herts & Essex Fertility Centre.

Herts & Essex has more than 35 years of history, has helped bring more than 8,000 babies into the world and delivers more than 1,000 cycles each year. For FutureLife, the acquisition added a third UK clinic to its platform, alongside CRGH in London and BCRM in Bristol.

This is a classic consolidation deal: a pan-European fertility group, already backed by institutional capital, acquiring a high quality regional clinic to deepen its UK footprint.

Two deals in sixteen months is not, on its own, a wave. It is fair to ask whether this signals a maturing but selective market or simply a quieter one. We read it as the former, both deals involved either a scaled platform or a high quality independent asset, which is exactly the pattern you would expect as a market consolidates and the number of obvious targets shrinks. What the two transactions do tell us clearly is that capital is still available for the right assets, and that quality is now the deciding factor rather than mere sector exposure.

The market is already more consolidated than many people realise

The HFEA’s 2024/25 sector report shows that there were 107 licensed fertility treatment clinics in the UK.

Of those, 71 were privately owned. Of the private clinics, 49 were owned by clinic groups and 22 were standalone.

That is a key point. The UK market is still fragmented in places, but it is no longer dominated by small independent clinics. Most private treatment clinics now sit within clinic groups.

That matters for valuations. Independent clinics with meaningful scale, strong local reputation and robust clinical governance are increasingly scarce, and scarcity tends to support buyer interest, particularly where a clinic can provide regional density or access to a strategically important location.

It also matters for how owners should think about timing. A standalone clinic remains attractive, but buyers are more selective than they were. They will want to understand consultant dependency, embryology team depth, patient acquisition, HFEA outcomes, inspection history, pricing, NHS exposure, capacity constraints and the quality of operational reporting.

The wider fertility value chain is attracting capital

Investor interest has continued to broaden beyond clinics themselves, and some of this activity sits directly in the operating infrastructure of IVF.

In June 2025, ReproTech invested in Matcher Technologies, the UK based business behind IMT Matcher, an electronic witnessing and traceability system used in fertility clinics. As clinics scale, governance, traceability, compliance and patient safety become even more important, and technology that reduces clinical risk or improves workflow is likely to remain attractive to investors and strategic acquirers.

In July 2025, Fertifa acquired Juniper Reproductive Health, bringing together reproductive health benefits and reproductive health insurance. This is not clinic M&A, but it is relevant: it shows the employer-funded route into reproductive healthcare is developing, and that fertility is increasingly viewed as part of a broader workplace health and benefits proposition.

Alongside this, the sector has seen early-stage venture activity. IVFmicro, a University of Leeds spinout, raised £3.5 million in pre-seed funding in December 2025 to develop microfluidic technology intended to improve embryo quality and quantity, and Jack Fertility secured over £500,000 of pre-seed investment for home-to-lab male fertility testing.

These are small, early-stage rounds rather than M&A, and they should be read as a signal of where founders and venture capital see future demand (in diagnostics, lab technology, male fertility and patient access) rather than as evidence of clinic deal momentum. The direction of travel across the value chain is nonetheless clear, and it sits alongside clinic consolidation rather than replacing it.

Regulation and governance are becoming more important

The fertility sector has always been highly regulated, but the regulatory environment is becoming more central from an investor perspective.

The NICE update discussed above is part of a wider push to reduce variation in practice and improve how fertility problems are investigated and managed. At the same time, the HFEA has continued to highlight the need for modernisation of fertility law, particularly given the growth of online services, fragmented patient journeys and new routes into treatment.

There has also been growing scrutiny of treatment add-ons, advertising claims and clinic governance. This is a double edged dynamic that sellers should plan for. For buyers, it means diligence will focus heavily on clinical governance, inspection history, consent processes, lab procedures, complaints, incidents, marketing practices and the extent to which revenue depends on treatments with limited evidence. For clinics whose economics lean on add-ons, tighter scrutiny is a real revenue risk and a diligence flashpoint.

For good operators, higher regulatory expectations are a net positive: they tend to favour businesses with proper systems, strong leadership and the ability to invest in quality. For weaker operators, the market is becoming less forgiving.

What this means for M&A

The fertility market remains attractive, but it is not a simple roll-up story and we would caution against either of the two easy narratives.

The bullish version (fertility is growing, private equity likes it, so transactions will keep flowing) is broadly directionally right but glosses over how selective buyers have become. The bearish version (only two clinic deals in over a year, so the market is cooling) over reads a small sample and ignores the capital still moving across the value chain. The more accurate picture sits between the two: demand fundamentals are strong, capital is available, but it is increasingly concentrated on assets with clear strategic value.

That value could mean scale, geography, clinical reputation, brand strength, technology, differentiated patient acquisition, strong outcomes, or the ability to plug into a broader platform.

It is also worth being candid about the risks, because they shape both timing and value. Add-on scrutiny could dent revenue at clinics over-exposed to it. The gap between NICE guidance and NHS commissioning introduces some uncertainty into the private-pay thesis, even if we think it is modest. As with any sector that has already seen its most obvious assets trade, sellers should not assume that strong headline interest automatically translates into a competitive process for every business. Preparation, positioning and timing matter more now than they did even a year ago.

For independent clinic owners, this creates both opportunity and pressure. The opportunity is that good fertility businesses remain scarce, and a well run independent clinic with strong outcomes, low consultant dependency and a clear growth story should continue to attract genuine interest. The pressure is that buyers have become more sophisticated and will want evidence, not just narrative (detailed KPI reporting, visibility over treatment volumes, conversion rates, pricing, add-ons, clinician productivity, embryology capacity, patient source, enquiry conversion, donor activity, storage income and cohort-level outcomes).

Outlook

Over the next 12 to 24 months, we expect fertility M&A to remain active, but not necessarily high volume.

There are likely to be further bolt-on acquisitions by existing groups, particularly where regional density can be improved, and potentially further sponsor to sponsor transactions involving larger platforms. The more structural development may be the continued expansion of the fertility value chain: fertility benefits, male fertility testing, lab workflow software, genetic testing, AI-supported decision tools, cryostorage, traceability and patient engagement platforms are all likely to attract attention.

The sector has moved beyond a narrow clinic consolidation thesis. The market is now about scale, quality, data, access and trust. For owners, this is about being ready to evidence all five.

That readiness is rarely built overnight. The clinics that achieve the strongest outcomes tend to be those that start preparing well before they intend to transact, getting their reporting, governance and growth story into the shape a sophisticated buyer now expects.

If you are weighing your options, that is the conversation we would encourage you to start early, and it is one we are always happy to have.